Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2021-01-19 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Preliminary Prospectus Supplement (to prospectus dated January 11, 2021)
Regulatory Filings Classification · 99% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a 'Preliminary Prospectus Supplement'. A prospectus supplement is a document related to the offering of securities, which falls under financing activities or capital structure changes. The document itself is very short (1909 characters) and explicitly states: 'Attached hereto is a report on*Preliminary Prospectus Supplement...*'. According to Rule 2, when a short document announces the publication of a specific report, it should be classified as a Report Publication Announcement (RPA). While it relates to capital raising (CAP), the nature of this specific filing is the *announcement* of the supplement's availability.
2021-01-19 English
Announces $10 Million Bought Deal Offering
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a $10 million 'bought deal offering' of American Depositary Shares (ADSs). It details the underwriting agreement, the number of shares, the price, the intended use of proceeds, and references a shelf registration statement. This falls squarely under the definition of a capital raising or financing activity update.
2021-01-19 English
Announces $10 Million Bought Deal Offering
Capital/Financing Update Classification · 98% confidence The document is a short regulatory filing (1836 characters) from BioLineRx, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. The title explicitly states 'BioLineRx Announces $10 Million Bought Deal Offering' and the body contains the line 'Attached hereto is a report on*BioLineRx Announces $10 Million Bought Deal Offering* *FWP_19-Jan-2021_isa.pdf'. This structure indicates an announcement about a financing event (offering/capital raise) where the detailed document is attached or linked, rather than the full report itself. The core subject is a capital raise ('Bought Deal Offering'). This aligns best with the 'Capital/Financing Update' category (CAP). Although it is an announcement, the specific nature of the announcement (financing) overrides the general 'RPA' classification, as 'CAP' is more descriptive of the content's substance.
2021-01-19 English
FWP
Regulatory Filings
2021-01-19 English
424B5
Regulatory Filings
2021-01-19 English
Regulatory Filings 2021
Regulatory Filings
2021-01-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.